- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Vitrafy Life Sciences Reports Strong US Army Platelet Preservation Results | 17 | smallcaps.com.au | ||
| Do | VITRAFY LIFE SCIENCES LIMITED: Phase 2 USAISR Platelet Results Investor Presentation | - | ASX | ||
| Do | VITRAFY LIFE SCIENCES LIMITED: Phase 2 USAISR Platelet Results Investor Briefing | - | ASX | ||
| Do | VITRAFY LIFE SCIENCES LIMITED: Final US Army Phase 2 Platelet Results | - | ASX | ||
| 28.04. | Vitrafy Q3 FY26 slides: military validation drives market expansion | 2 | Investing.com | ||
| 27.04. | VITRAFY LIFE SCIENCES LIMITED: Quarterly Investor Briefing Presentation | - | ASX | ||
| VITRAFY LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 27.04. | VITRAFY LIFE SCIENCES LIMITED: Q3 FY26 Quarterly Activities Report and Appendix 4C | - | ASX | ||
| 23.04. | VITRAFY LIFE SCIENCES LIMITED: Vitrafy Q3 FY26 Investor Briefing | - | ASX | ||
| 07.04. | VITRAFY LIFE SCIENCES LIMITED: USAISR Completes Phase 2 Platelet Study | - | ASX | ||
| 25.03. | VITRAFY LIFE SCIENCES LIMITED: NWR Virtual Healthcare Conference Presentation | - | ASX | ||
| 24.03. | VITRAFY LIFE SCIENCES LIMITED: Vitrafy to present at NWR Virtual Healthcare Conference | 2 | ASX | ||
| 19.02. | VITRAFY LIFE SCIENCES LIMITED: Change of Director's Interest Notice | 2 | ASX | ||
| 03.02. | VITRAFY LIFE SCIENCES LIMITED: FY26 Appendix 4D and Half Year Report | - | ASX | ||
| 03.02. | VITRAFY LIFE SCIENCES LIMITED: FY26 Half Year Results Presentation | - | ASX | ||
| 02.02. | VITRAFY LIFE SCIENCES LIMITED: Vitrafy FY26 Half Year Investor Briefing | - | ASX | ||
| 29.01. | Vitrafy Life Sciences Q2 FY26 slides highlight animal health deal and U.S. expansion | 2 | Investing.com | ||
| 28.01. | VITRAFY LIFE SCIENCES LIMITED: Vitrafy Q2 FY26 Investor Briefing | 2 | ASX | ||
| 19.01. | VITRAFY LIFE SCIENCES LIMITED: Initial Director's Interest Notice | - | ASX | ||
| 19.01. | VITRAFY LIFE SCIENCES LIMITED: Appointment of Independent Non-Executive Director | - | ASX | ||
| 19.01. | VITRAFY LIFE SCIENCES LIMITED: Change in substantial holding from RYD | - | ASX |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 16,620 | 0,00 % | This Summit Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Friday | ||
| CG ONCOLOGY | 64,25 | 0,00 % | Wolfe Research startet Coverage für CG Oncology mit "Peerperform" | ||
| QIAGEN | 30,290 | +0,65 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,240 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 343,26 | -0,09 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,640 | -0,09 % | Cogent Biosciences: Aktie legt vor wichtigen Studiendaten um 4 % zu | ||
| GEOVAX LABS | 3,630 | -0,27 % | EQS-News: GeoVax, Inc.: GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms | EQS-News: GeoVax, Inc.
/ Key word(s): Science
GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms 20.05.2026 / 16:06... ► Artikel lesen | |
| METAVIA | 3,850 | 0,00 % | MetaVia: Präklinische Studie zu Vanoglipel untermauert Potenzial bei Lebererkrankungen | ||
| IMMUNEERING | 5,390 | 0,00 % | Immuneering Corporation: Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy | - Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 - - Tolerability profile consistent with prior updates: only two categories of Grade... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,535 | +0,04 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,490 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update | Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following... ► Artikel lesen | |
| IMMUNOVANT | 34,140 | -0,03 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,640 | 0,00 % | Beam Therapeutics presents AATD gene therapy trial data at ATS | ||
| INHIBRX BIOSCIENCES | 101,45 | +0,13 % | Inhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2026 Financial Results | SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,005 | -0,17 % | Morgan Stanley Raises its Price Target on Recursion (RXRX) |
Das Unternehmen VITRAFY LIFE SCIENCES LIMITED kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VITRAFY LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.